Company Hemispherx BioPharma, Inc Nyse
Equities
US42366C1036
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
Business Summary
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Ampligen and Other Drugs
100.0
%
| 0 | 100.0 % | 0 | 100.0 % | +43.26% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 0 | 100.0 % | 0 | 100.0 % | +43.26% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Thomas Equels
CEO | Chief Executive Officer | 71 | 08-11-16 |
Robert Dickey
DFI | Director of Finance/CFO | 68 | 22-04-03 |
Chief Tech/Sci/R&D Officer | - | 22-05-31 | |
Peter Rodino
COO | Chief Operating Officer | 72 | 13-07-22 |
David R. Strayer
CTO | Chief Tech/Sci/R&D Officer | 78 | 85-12-31 |
Jenene Thomas
IRC | Investor Relations Contact | 52 | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Nancy K. Bryan
BRD | Director/Board Member | 66 | 23-03-27 |
William Mitchell
CHM | Chairman | 89 | 98-06-30 |
Thomas Equels
CEO | Chief Executive Officer | 71 | 08-11-16 |
Peter Rodino
COO | Chief Operating Officer | 72 | 13-07-22 |
Director/Board Member | 70 | 16-07-31 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 49,901,177 | 45,415,144 ( 91.01 %) | 0 | 91.01 % |
Stock B | 0 | 689 | 0 | 0 |
Company contact information
Sector
1st Jan change | Capi. | |
---|---|---|
-1.51% | 104B | |
+3.22% | 97.42B | |
+1.78% | 22.2B | |
-16.53% | 21.23B | |
-9.10% | 18.33B | |
-42.33% | 16.35B | |
-20.09% | 15.06B | |
+5.47% | 13.98B | |
+28.85% | 11.66B |
- Stock Market
- Equities
- AIM Stock
- Stock
- Company Hemispherx BioPharma, Inc